المؤلفون: Kudo, Masatoshi, Finn, Richard S, Ikeda, Masafumi, Sung, Max W, Baron, Ari D, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Meyer, Tim, Nagao, Satoshi, Saito, Kenichi, Mody, Kalgi, Ramji, Zahra, Dubrovsky, Leonid, Llovet, Josep M

المصدر: Liver Cancer (2023) (In press).

مصطلحات موضوعية: Hepatocellular carcinoma, Lenvatinib, Pembrolizumab, Progression-free survival, Overall survival

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10187904/1/000535154.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10187904Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10187904/1/000535154.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10187904Test/

المؤلفون: Piscaglia, Fabio, Ikeda, Kenji, Cheng, Ann‐Lii, Kudo, Masatoshi, Ikeda, Masafumi, Breder, Valery, Ryoo, Baek‐Yeol, Mody, Kalgi, Ren, Min, Ramji, Zahra, Sung, Max W.

المصدر: Cancer (0008543X); Apr2024, Vol. 130 Issue 8, p1281-1291, 11p

مصطلحات موضوعية: HEPATOCELLULAR carcinoma, PROTEIN-tyrosine kinase inhibitors, HYPERTENSION, OVERALL survival, PROGRESSION-free survival

المؤلفون: Motzer, Robert, Porta, Camillo, Alekseev, Boris, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, Cella, David

المساهمون: Motzer, Robert, Porta, Camillo, Alekseev, Bori, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, Cella, David

مصطلحات موضوعية: CLEAR study, lenvatinib, pembrolizumab, sunitinib, progression-free survival, overall survival, advanced renal cell carcinoma

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35489363; info:eu-repo/semantics/altIdentifier/wos/WOS:000831830800022; volume:23; issue:6; firstpage:768; lastpage:780; numberofpages:13; journal:THE LANCET ONCOLOGY; https://hdl.handle.net/11586/464740Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131115613

الإتاحة: https://doi.org/10.1016/s1470-2045Test(22)00212-1
https://hdl.handle.net/11586/464740Test

المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

المؤلفون: Llovet, Josep M., Vogel, Arndt, Madoff, David C., Finn, Richard S., Ogasawara, Sadahisa, Ren, Zhenggang, Mody, Kalgi, Li, Jerry J., Siegel, Abby B., Dubrovsky, Leonid, Kudo, Masatoshi

المصدر: CardioVascular & Interventional Radiology; Apr2022, Vol. 45 Issue 4, p405-412, 8p

مصطلحات موضوعية: HEPATOCELLULAR carcinoma, PROGRESSION-free survival, SAMPLE size (Statistics), PEMBROLIZUMAB, OVERALL survival

المؤلفون: Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, Kumada, Hiromitsu

المصدر: Journal of Gastroenterology; Jun2021, Vol. 56 Issue 6, p570-580, 11p

مصطلحات موضوعية: BODY weight, HEPATOCELLULAR carcinoma, OVERALL survival, SURVIVAL rate, PROGRESSION-free survival

المؤلفون: Grünwald, Viktor, Powles, Thomas, Choueiri, Toni K, Hutson, Thomas E, Porta, Camillo, Eto, Masatoshi, Sternberg, Cora N, Rha, Sun Young, He, Cixin S, Dutcus, Corina E, Smith, Alan, Dutta, Lea, Mody, Kalgi, Motzer, Robert J

المصدر: Future Oncology; Mar2019, Vol. 15 Issue 9, p929-941, 13p